A Phase 3 interventional study of Placebo + ADT and Brexpiprazole +ADT in Depressive Disorder, Depression and Depressive Disorder, Major, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 47 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 15th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 837 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 11th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2014, is one of 23 in phase 3, and was the 28th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress
The introduction of atypical antipsychotics has created a renewed interest in adjunctive therapy for MDD, particularly for treatment-resistant MDD. Several atypical antipsychotics have been shown to enhance the response to ADT. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial designed to assess the safety and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy to an assigned open-label ADT in depressed subjects with and without anxious distress.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
This study's enrollment of 837 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Compared within Depressive Disorder, Major, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Brexpiprazole + ADT
Drug: Brexpiprazole +ADT
Placebo + ADT
Drug: Placebo + ADT
Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
Drug pages: Brexpiprazole · Antiandrogens
Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
Change in the Montgomery-Asberg Depression
To assess the change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score from Baseline (End of Phase A \[Week 8\]) to Week 14. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The rater decided whether the rating lied on predefined scale steps (0, 2, 4, 6) or between them (1, 3, 5). The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.
Time frame: From baseline (end of Phase A [Week 8]) to week 14
Change in the Sheehan Disability Scale (SDS) From Baseline to End of Treatment
To assess the change in the Sheehan Disability Scale (SDS) Score (the mean of 3 individual item scores) from Baseline (End of Phase A \[Week 8\]) to Week 14 (End of Phase B). SDS was a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life, and family life/home responsibility. Each item was scored using a scale of 0 to 10 (a higher score indicates symptoms have disrupted work, social life, and family life/home responsibility extremely). The maximum total score was 30; 0 = not at all, to 30 = extremely.
Time frame: From baseline (end of Phase A [Week 8]) to week 14
Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulation With <25% Improvement From Baseline of Phase A to End of Phase A in MADRS Total Score
To assess the change from end of Phase A (Week 8 visit) to end of Phase B (Week 14 visit) in MADRS Total Score for the subpopulation with \< 25% improvement from baseline of Phase A (Week 0) to end of Phase A (Week 8) in MADRS Total Score. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.
Time frame: From baseline (end of Phase A [Week 8]) to week 14
Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulations With Anxious Distress as Specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
To assess the change from end of Phase A (Week 8) to end of Phase B (Week 14) in MADRS Total Score for the subpopulations with anxious distress as specified in DSM-V. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.
Time frame: From baseline (end of Phase A [Week 8]) to week 14
This trial was conducted in 837 participants at 51 trial sites in the following 5 countries:Germany,Hungary,Poland,Slovakia,andUnited States (US).A total of 1144 participants with major depressive disorder were screened for the trial, 837 enrolled into Phase A,394 were randomized into Phase B and 322 continued treatment with placebo+ADT in Phase A+
| Milestone | Phase A: All ADT (Antidepressant Therapy) | Phase B: Brexpiprazole + ADT | Phase B: Placebo + ADT | Phase A +: ALL ADT |
|---|---|---|---|---|
| Started | 837 | 0 | 0 | 0 |
| Completed | 716 | 0 | 0 | 0 |
| Not completed | 121 | 0 | 0 | 0 |
| Withdrew: Participant met withdrawal criteria | 34 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 34 | 0 | 0 | 0 |
| Withdrew: Adverse event | 22 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 9 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 12 | 0 | 0 | 0 |
| Withdrew: Participant withdrawn by investigator | 10 | 0 | 0 | 0 |
| Milestone | Phase A: All ADT (Antidepressant Therapy) | Phase B: Brexpiprazole + ADT | Phase B: Placebo + ADT | Phase A +: ALL ADT |
|---|---|---|---|---|
| Started | 0 | 192 | 202 | 0 |
| Completed | 0 | 177 | 196 | 0 |
| Not completed | 0 | 15 | 6 | 0 |
| Withdrew: Participant met withdrawal criteria | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 2 | 0 |
| Withdrew: Withdrawal by participant | 0 | 8 | 1 | 0 |
| Withdrew: Adverse event | 0 | 4 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 0 |
| Milestone | Phase A: All ADT (Antidepressant Therapy) | Phase B: Brexpiprazole + ADT | Phase B: Placebo + ADT | Phase A +: ALL ADT |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 322 |
| Completed | 0 | 0 | 0 | 308 |
| Not completed | 0 | 0 | 0 | 14 |
| Withdrew: Participant met withdrawal criteria | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by participant | 0 | 0 | 0 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 6 |
| Withdrew: Participant withdrawn by investigator | 0 | 0 | 0 | 1 |
To assess the change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score from Baseline (End of Phase A \[Week 8\]) to Week 14. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The rater decided whether the rating lied on predefined scale steps (0, 2, 4, 6) or between them (1, 3, 5). The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.
| Units on a scale | Brexpiprazole + ADT | Placebo + ADT |
|---|---|---|
| Change in the Montgomery-Asberg Depression | -10.4 ± 0.63 | -8.07 ± 0.61 |
To assess the change in the Sheehan Disability Scale (SDS) Score (the mean of 3 individual item scores) from Baseline (End of Phase A \[Week 8\]) to Week 14 (End of Phase B). SDS was a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life, and family life/home responsibility. Each item was scored using a scale of 0 to 10 (a higher score indicates symptoms have disrupted work, social life, and family life/home responsibility extremely). The maximum total score was 30; 0 = not at all, to 30 = extremely.
| Units on a scale | Brexpiprazole + ADT | Placebo + ADT |
|---|---|---|
| Change in the Sheehan Disability Scale (SDS) From Baseline to End of Treatment | -1.63 ± 0.18 | -1.41 ± 0.17 |
To assess the change from end of Phase A (Week 8 visit) to end of Phase B (Week 14 visit) in MADRS Total Score for the subpopulation with \< 25% improvement from baseline of Phase A (Week 0) to end of Phase A (Week 8) in MADRS Total Score. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.
| Units on a scale | Brexpiprazole + ADT | Placebo + ADT |
|---|---|---|
| Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulation With <25% Improvement From Baseline of Phase A to End of Phase A in MADRS Total Score | -11.1 ± 0.71 | -8.87 ± 0.71 |
To assess the change from end of Phase A (Week 8) to end of Phase B (Week 14) in MADRS Total Score for the subpopulations with anxious distress as specified in DSM-V. The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). The MADRS consisted of 10 items each with 7 defined grades of severity. The 10 items were apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. Each item was scored using a scale of 0 to 6 (a higher score indicates increased severity). The maximum total score was 60; 0, no symptom; 60, severely affected.
| Units on a scale | Brexpiprazole + ADT | Placebo + ADT |
|---|---|---|
| Change From End of Phase A to End of Phase B in MADRS Total Score for the Subpopulations With Anxious Distress as Specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). | -11.8 ± 0.81 | -8.87 ± 0.81 |
Collected over Participants were assessed for the occurrence of adverse events (AEs) once the participant signed informed consent form through completion of the trial; up to 14-weeks after the participant entered the trial and actively monitored up to 30 (+2) days after their last dose of investigational medicinal product (this could be up to 22 weeks depending on duration of trial participation).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole + ADT | 0/192 (0%) | 1/192 (0.5%) | 49/192 (25.5%) |
| Placebo + ADT | 0/202 (0%) | 0/202 (0%) | 35/202 (17.3%) |
| Event | Brexpiprazole + ADT | Placebo + ADT |
|---|---|---|
| VertigoEar and labyrinth disorders | 1/192 | 0/202 |
| Event | Brexpiprazole + ADT | Placebo + ADT |
|---|---|---|
| AkathisiaNervous system disorders | 16/192 | 10/202 |
| RestlessnessPsychiatric disorders | 16/192 | 4/202 |
| HeadacheNervous system disorders | 7/192 | 15/202 |
| Upper Respiratory Tract InfectionInfections and infestations | 10/192 | 10/202 |
| Weight IncreasedInvestigations | 10/192 | 1/202 |
Baseline measures are based on the participants from the Double-blind Randomization Phase
| Age, Continuous(years) | Brexpiprazole + ADT | Placebo + ADT | Total |
|---|---|---|---|
| Mean | 43.0 ± 12.7 | 42.7 ± 12.5 | 42.9 ± 12.6 |
| Sex: Female, Male(Participants) | Brexpiprazole + ADT | Placebo + ADT | Total |
|---|---|---|---|
| Female | 147 | 144 | 291 |
| Male | 45 | 58 | 103 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole + ADT | Placebo + ADT | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 9 | 20 |
| Not Hispanic or Latino | 181 | 192 | 373 |
| Unknown | 0 | 1 | 1 |
| Region of Enrollment(participants) | Brexpiprazole + ADT | Placebo + ADT | Total |
|---|---|---|---|
| Hungary | 16 | 16 | 32 |
| United States | 100 | 106 | 206 |
| Poland | 26 | 26 | 52 |
| Slovakia | 23 | 25 | 48 |
| Germany | 27 | 29 | 56 |
The record gives a start of Jul 2014, a primary completion of Apr 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brexpiprazole · Antiandrogens
Otsuka Pharmaceutical Development & Commercialization, Inc. →